Thus, the individual molecular background of bladder cancer patients, including biallelic ATR or PRKDC deficiencies, should be considered in future studies, which may finally allow treatment of patients with a single drug but with comparable efficacy of tumor cell lethality. This evidence concerns the gene ATR and urinary bladder carcinoma.